HemAcure - Team
HemAcure - Team
HemAcure - Team

Partner 3 - Università del Piemonte Orientale "Amedeo Avogadro"

Antonia Follenzi

 

Università del Piemonte Orientale

Prof. Antonia Follenzi

 

Principal Investigator

Leader WP2

 

undefinedE-Mail

Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

 

Via Solaroli 17

28100 Novara

Italy

 

undefinedWebsite

HemAcure Team Università del Piemonte Orientale "Amedeo Avogadro"

Simone Merlin

Cristina Olgasi

Dr. Simone Merlin

 

Senior Postdoc

 

Phone +39 0321 660679     
undefinedE-Mail

 

Dr. Cristina Olgasi

 

Postdoc

 

Phone +39 0321 660664  
undefinedE-Mail

Valentina Bruscaggin

Bsc. Valentina Bruscaggin

 

Lab Technician

   
undefinedE-Mail

Institute presentation

The School of Medicine of the Università del Piemonte Orientale “Amedeo Avogadro“ combines the Department of Health Sciences (DHS) and the Department of Translational Medicine and is devoted to basic science and translational research in the field of Medicine, in strict collaboration with the top-quality hospital (AOU Maggiore della Carità).
The DHS, is a multi-disciplinary research environment with strong emphasis on both developments of new technologies and clinical translation. The mission of the DHS is to perform cutting edge science in the field of liver diseases, tumor biology, tissue engineering, gene therapy, genetic and immunology and to promote the translation of basic discoveries into therapeutic advances.
Fully equipped labs are available at UPO to perform molecular biology, cell culture, imaging, biochemical assays. Instrument facilities include: BSL2 class laboratory, flow cytometer and ultracentrifuge for Lentiviral vectors (LVs) concentration and confocal microscope. Animal facilities include 5 rooms for rabbit, small and big rodents, 1 for immuno-compromised mice and 2 for animal manipulation and surgery.
More information about UPO can be obtained at the undefinedwebsite.

The main tasks of UPO within the project will be the preparation of LVs containing the FVIII gene for the transduction of BOECs from haemophilia A patients (undefinedWP2). Moreover, UPO will participate in the characterisation of the FVIII-corrected BOECs concerning their safety potential (undefinedWP4) and in vivo implantation in an immunocompromised mouse model of haemophilia A (undefinedWP5).

HemAcure Consortium

HemAcure Consortium
Search
Home
Top

HemAcure on @twitter

News Section

HemAcure is proud to be example in Roland Berger article about Regenerative...

Read more

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

Social Media

Follow us on Twitter! @HemAcure_EU